Biogen Idec to Present at the Sanford Bernstein 23rd Annual Strategic Decisions Conference 2007.CAMBRIDGE, Mass. -- Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BIIB BIIB Basic Imagery Interpretation Brief ) announced today that its presentation at the Sanford Bernstein 23rd Annual Strategic Decisions Conference 2007 will be webcast live via the internet, on Friday, June 1 at 10:00 a.m. ET. To access the live webcast, please visit Biogen Idec's homepage, www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion